Journal of the American Medical Directors Association
Trials in this field remain small, and most are undertaken in oncology patients. Much research has focused on appetite stimulation (mostly using megestrol acetate), anti- inflammatory pathways, and anabolics. Ghrelin has shown some potential in clinical trials as has enobosarm. Results of the POWER trial with enobosarm, one of the few large-scale trials to improve muscle mass and function in patients with advanced cancer, are eagerly awaited. In addition, results of the ACT-ONE trial using the anabolic/catabolic transforming agent espindolol have shown promising results.
Luces y sombras en el debate de la medicalización de la muerte.